title: Intravenous immunoglobulin and multiple sclerosis.
abstract: Intravenous immunoglobulin (IVIg) has been used as an immunomodulatory therapy for the treatment of multiple sclerosis (MS). In the current review, we summarize the up-to-date data related to IVIg clinical trials in MS, and the suggested mechanisms of action by which IVIg modulates the relevant immunological pathways impaired in MS.
authors.affiliation: Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Israel. achiron@post.tau.ac.il
authors.forename: Anat
authors.initials: A
authors.lastname: Achiron
authors.forename: Shmuel
authors.initials: S
authors.lastname: Miron
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000276:immunology* / Q000627:therapeutic use*; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology*; D011247:Pregnancy
chemical_list: D000276:Adjuvants, Immunologic; D016756:Immunoglobulins, Intravenous; D016899:Interferon-beta; D000068556:Interferon beta-1a